Sara Hurvitz, MD, Spoke on Efficacy of T-DXd in HER2+ Breast Cancer With Brain Metastases

In an interview with CancerNetwork® Sara Hurvitz, MD, associate professor at the David Geffen School of Medicine, medical director of the Johnson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa-Monica- University of California Los Angeles (UCLA) Outpatient Oncology Practices, and director of the Breast Cancer Clinical Trials Program at the University of California Los Angeles, spoke about additional clinical trials that are ongoing for the research of patients with or without brain metastases who have had previously treated metastatic HER2-positive breast cancer. Patients will be treated with fam-trastuzumab deruxtecan (T-DXd; Enhertu) with primary end points of objective response rate and progression-free survival.

Transcript:

The data relating to T-DXd for patients who have brain metastases are also exciting. We have a subgroup analysis from the Destiny-Breast03 trial that indicates about 60% of patients can have an intracranial objective response with T-DXd, which is higher than seen with T-DM1. These patients didn’t have progressive brain metastases or symptomatic brain metastases, but the data are nonetheless very intriguing from the [phase 2] TUXEDO-1 study (NCT04752059) which were presented as ESMO Breast further provides support that T-DXd may be active in progressive or untreated brain metastases. I’m really excited to see studies like [the phase 3] DESTINEY-Breast12 [trial; DESTINEY-Breast-12] provide further data in this area of unmet need for HER2-positive disease.